Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners.

Autor:	Schwartz S; Bachelor of Sciences Candidate, Department of Psychology, High Point University School of Humanities and Behavioral Sciences, High Point, North Carolina.; Core Faculty Member, Psychiatry Residency Program, Community Hospital North Behavioral Health Pavilion, Indianapolis, Indiana.; Clinical Pharmacy Specialist, Department of Psychiatry, Community Hospital North Behavioral Health Pavilion, Indianapolis, Indiana.; Medical Director, Department of Psychiatry, Cone Health Behavioral Health Hospital, Greensboro, North Carolina., Carilli C; Bachelor of Sciences Candidate, Department of Psychology, High Point University School of Humanities and Behavioral Sciences, High Point, North Carolina., Mian T; Core Faculty Member, Psychiatry Residency Program, Community Hospital North Behavioral Health Pavilion, Indianapolis, Indiana., Ruekert L; Clinical Pharmacy Specialist, Department of Psychiatry, Community Hospital North Behavioral Health Pavilion, Indianapolis, Indiana., Kumar A; Medical Director, Department of Psychiatry, Cone Health Behavioral Health Hospital, Greensboro, North Carolina.
Jazyk:	angličtina
Zdroj:	The mental health clinician [Ment Health Clin] 2022 Aug 23; Vol. 12 (4), pp. 232-240. Date of Electronic Publication: 2022 Aug 23 (Print Publication: 2022).
DOI:	10.9740/mhc.2022.08.232
Abstrakt:	Introduction: Long-acting injectable antipsychotics (LAI-As) are important tools for the treatment of schizophrenia, yet they appear to be underutilized. This study will assess practitioner perceptions of LAI-As to elucidate reasons for underuse and uncover new avenues to increase appropriate use. Methods: An anonymous electronic survey was developed and actively distributed to behavioral health care practitioners (MD, DO, PA, NP, PharmD, RN, LCSW). Independent t testing and linear regression analysis was used to assess for interactions between survey responses and individual factors. Results: A total of 146 survey responses were collected from September 3, 2020 to March 17, 2021. On average, participants thought that LAI-As were slightly underutilized in practice. The mean estimated patient acceptance rate for LAI-A therapy was 38.6% ± 29.5% (range = 0%-100%). Participants who were <40 years of age and those with a psychiatric pharmacist at their practice site had significantly higher estimated acceptance rates. The highest-rated barriers to LAI-A use were related to negative patient attitudes, lack of patient education, and access issues (eg, transportation, cost). Respondent characteristics including age, gender identity, geographic location, practice setting, and the presence of a psychiatric pharmacist significantly influenced the perceived impact of these barriers. Discussion: Behavioral health practitioners generally believed that LAI-As were underused, and only one-third of their patients would be accepting of the therapy. Several barriers were perceived as frequently impacting LAI-A use, but these were reduced by the presence of a psychiatric pharmacist. Understanding practitioner perceptions can assist with increasing the use of LAI-As. Competing Interests: Disclosures: The authors have no conflicts of interest to disclose. (© 2022 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu